Sector News

UCB acquires gene therapy specialist Handl Therapeutics

November 13, 2020
Life sciences

Company also announces new collaboration with Lacerta Therapeutics.

UCB has announced its acquisition of Belgium-based gene therapy company Handl Therapeutics, in a move that will bolster its pipeline programmes, capabilities and platforms in the gene therapy space.

UCB also announced a new collaboration with Lacerta Therapeutics, a clinical stage gene therapy company based in Florida, US.

Handl Therapeutics is focused on creating disease modifying in vivo gene therapies to treat neurodegenerative disease through proprietary adeno-associated virus (AAV) capsid technology.

According to UCB, Handl has a strong international network which enables access to global capabilities and expertise – the company combines technology platforms and scientific advances licenced from KU Leuven (Belgium), Centre for Applied Medical Research (CIMA Universidad de Navarra, Spain), University of Chile (Chile) and King’s College London (UK).

Following the acquisition by UCB, the Handl Therapeutics team will continue to be based in Leuven, Belgium while working closely with UCB’s international research teams.

In addition to its acquisition of Handl Therapeutics, UCB has also signed a research collaboration and licensing agreement with Lacerta Therapeutics.

The focus of this agreement is to make AAV-based therapies for central nervous system (CNS) diseases with high unmet need.

Lacerta is set to lead the research, preclinical activities and early manufacturing process development, while UCB will lead IND-enabling studies, manufacturing and clinical development.

“The acquisition of Handl Therapeutics and the new partnership with Lacerta Therapeutics offers us the potential to drive a fundamental change in how diseases are treated, by moving us from treating symptoms to disease modification and eventually towards a cure,” said Dhavalkumar Patel, chief scientific officer of UCB.

“We are delighted to be able to welcome a rich diversity of talent and expertise from both Handl Therapeutics and Lacerta Therapeutics. With their deep and wide-ranging knowledge, novel gene therapy platforms and drive for innovation, I am confident that together we will transform the lives of people living with severe neurodegenerative diseases,” he added.

by Lucy Parsons

Source: pharmatimes.com

Related News

March 6, 2021

Takeda takes full control of drug for rare epilepsies

Life sciences

The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones. 

March 6, 2021

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

Life sciences

Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.

March 6, 2021

Disney teams with Philips to bring its characters to pediatric imaging

Life sciences

A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.

Send this to a friend